Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
BBO-10203 is a first-in-class orally bioavailable RAS:PI3Ka breaker that blocks the interaction between RAS and PI3Kα to inhibit PI3Kα-AKT signaling in tumors.
Lead Product(s): BBO-10203,Trastuzumab
Therapeutic Area: Oncology Brand Name: BBO-10203
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2024
Lead Product(s) : BBO-10203,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
BridgeBio Doses First Patient with BBO-10203 in Phase 1 BREAKER-101 Trial
Details : BBO-10203 is a first-in-class orally bioavailable RAS:PI3Ka breaker that blocks the interaction between RAS and PI3Kα to inhibit PI3Kα-AKT signaling in tumors.
Brand Name : BBO-10203
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 30, 2024
Details:
HLX11 (pertuzumab biosimilar) is the HER2 humanized monoclonal antibody, which is being investigated for the treatment of HER2-positive/ HR-negative locally advanced breast cancer.
Lead Product(s): Pertuzumab,Trastuzumab,Docetaxel
Therapeutic Area: Oncology Brand Name: HLX11
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2024
Lead Product(s) : Pertuzumab,Trastuzumab,Docetaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Phase 3 Study of Perjeta® Biosimilar HLX11 Meets Primary Endpoint
Details : HLX11 (pertuzumab biosimilar) is the HER2 humanized monoclonal antibody, which is being investigated for the treatment of HER2-positive/ HR-negative locally advanced breast cancer.
Brand Name : HLX11
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 30, 2024
Details:
Hercessi (trastuzumab-biosimilar) is biosimilar to Herceptin, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric or gastroesophageal junction adenocarcinoma.
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Brand Name: Hercessi
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2024
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Accord BioPharma Gains FDA Approval of HERCESSI™ Biosimilar For Cancer
Details : Hercessi (trastuzumab-biosimilar) is biosimilar to Herceptin, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric or gastroesophageal junction adenocarcinoma.
Brand Name : Hercessi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 18, 2024
Details:
ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in combination with trastuzumab in patients with HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Brand Name: ALX148
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2024
Lead Product(s) : Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ALX Reports Phase 2 Data Showing Evorpacept Improves HER2-Positive Gastric Cancer Response
Details : ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in combination with trastuzumab in patients with HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer.
Brand Name : ALX148
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 31, 2024
Details:
Tuznue (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric adenocarcinoma.
Lead Product(s): Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area: Oncology Brand Name: Tuznue
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2024
Lead Product(s) : Trastuzumab,Docetaxel,Epirubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion
Details : Tuznue (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicatedfor the treatment of HER2 overexpressing breast cancer & metastatic gastric adenocarcinoma.
Brand Name : Tuznue
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 31, 2024
Details:
Mamitra, biosimilar of trastuzumab, is an anti-HER2 antibody-drug conjugate (ADC) which is being developed for HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Brand Name: Mamitra
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2024
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Gets Mexican Regulatory Approval to Market Cancer Treatment Product
Details : Mamitra, biosimilar of trastuzumab, is an anti-HER2 antibody-drug conjugate (ADC) which is being developed for HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).
Brand Name : Mamitra
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 31, 2024
Details:
The proceeds from the financing will be used to advance the IAM1363, a highly selective, brain-penetrant small molecule inhibitor, being evaluated for the treatment of HER2-mutated neoplasms.
Lead Product(s): IAM1363,Trastuzumab
Therapeutic Area: Oncology Brand Name: IAM1363
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Mubadala Capital
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 18, 2024
Lead Product(s) : IAM1363,Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Mubadala Capital
Deal Size : $150.0 million
Deal Type : Series B Financing
Iambic Closes $50M Series B Extension to Broaden AI-Discovered Oncology Programs
Details : The proceeds from the financing will be used to advance the IAM1363, a highly selective, brain-penetrant small molecule inhibitor, being evaluated for the treatment of HER2-mutated neoplasms.
Brand Name : IAM1363
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 18, 2024
Details:
Keytruda (pembrolizumab) is a USFDA approved anti PD-L1 monoclonal antibody. It is being evaluated in combination with trastuzumab for HER2-positive advanced gastroesophageal junction adenocarcinoma.
Lead Product(s): Pembrolizumab,Trastuzumab,Cisplatin
Therapeutic Area: Oncology Brand Name: Keytruda
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Lead Product(s) : Pembrolizumab,Trastuzumab,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck's KEYNOTE-811 Trial Meets Overall Survival Endpoint for HER2-Positive Gastric Cancer
Details : Keytruda (pembrolizumab) is a USFDA approved anti PD-L1 monoclonal antibody. It is being evaluated in combination with trastuzumab for HER2-positive advanced gastroesophageal junction adenocarcinoma.
Brand Name : Keytruda
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 01, 2024
Details:
Hercessi (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicated for HER2 overexpressing breast cancer & metastatic gastric or gastroesophageal junction adenocarcinoma.
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Brand Name: Hercessi
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Accord BioPharma’s HERCESSI™ (trastuzumab-strf) Approved as Herceptin® Biosimilar in U.S
Details : Hercessi (trastuzumab-biosimilar) is a HER2/neu receptor antagonist, which is indicated for HER2 overexpressing breast cancer & metastatic gastric or gastroesophageal junction adenocarcinoma.
Brand Name : Hercessi
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 29, 2024
Details:
The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar utilized in patients diagnosed with breast cancer or metastatic stomach cancer.
Lead Product(s): Trastuzumab
Therapeutic Area: Oncology Brand Name: Ogivri
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 10, 2024
Lead Product(s) : Trastuzumab
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Sandoz B2B
Deal Size : Undisclosed
Deal Type : Partnership
Biocon Biologics Partners with Sandoz for Biosimilars
Details : The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar utilized in patients diagnosed with breast cancer or metastatic stomach cancer.
Brand Name : Ogivri
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 10, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Australia
Brand Name : Herzuma
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Trastuzumab Cipla 440 mg
Dosage Form : INJ
Dosage Strength : 440mg
Packaging : 21X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info :
Registration Country : Sweden
Brand Name : Herceptin
Dosage Form : POWDER FOR CONCENTRATE FOR
Dosage Strength : 150 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Herceptin 21 mg/ml IV
Dosage Form : INJ
Dosage Strength : 440mg
Packaging : 21X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info :
Registration Country : Australia
Brand Name : Herceptin SC
Dosage Form : injection
Dosage Strength : 600 mg/5 mL
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kanjinti
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kanjinti
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kanjinti
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Trazimera
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Ogivri
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD :
TE Code :
Brand Name : HERCESSI
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 150MG
Approval Date :
Application Number : 761346
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : HERZUMA
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 420MG
Approval Date :
Application Number : 761091
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : TRAZIMERA
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 420MG
Approval Date :
Application Number : 761081
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : ONTRUZANT
Dosage Form : POWDER;IV (INFUSION)
Dosage Strength : 150MG
Approval Date :
Application Number : 761100
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : ONTRUZANT
Dosage Form : POWDER;IV (INFUSION)
Dosage Strength : 420MG
Approval Date :
Application Number : 761100
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : OGIVRI
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 420MG/VIAL
Approval Date :
Application Number : 761074
RX/OTC/DISCN :
RLD :
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Switzerland
Brand Name : Enhertu
Dosage Form : Inf Conc
Dosage Strength : 100mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Herceptin
Dosage Form : SOLUTION FOR INJECTION
Dosage Strength : 600 MG / 5 ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Herceptin
Dosage Form : SOLUTION FOR INJECTION IN
Dosage Strength : 600 MG / 5 ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Herceptin
Dosage Form : POWDER FOR CONCENTRATE FOR
Dosage Strength : 150 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Herceptin
Dosage Form : Trastuzumab 150Mg 1 Unit Parenteral Use
Dosage Strength : 1 vial groun EV 150 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Herceptin
Dosage Form : Trastuzumab 600Mg 1 Unit Parenteral Use
Dosage Strength : 1 vial SC 600 mg/5 ml 6 ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Phesgo
Dosage Form : Inj L?s
Dosage Strength : 1200mg/600mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Phesgo
Dosage Form : Inj L?s
Dosage Strength : 600mg/600mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : KANJINTI
Dosage Form : KIT
Dosage Strength : 420MG/VIAL
Packaging :
Approval Date :
Application Number : 2496690
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : HERZUMA
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 150MG/VIAL
Packaging :
Approval Date :
Application Number : 2506211
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : HERZUMA
Dosage Form : KIT
Dosage Strength : 440MG/VIAL
Packaging :
Approval Date :
Application Number : 2480794
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : HERCEPTIN SC
Dosage Form : SOLUTION
Dosage Strength : 600MG/5ML
Packaging :
Approval Date :
Application Number : 2480697
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PHESGO
Dosage Form : SOLUTION
Dosage Strength : 40MG/ML
Packaging :
Approval Date :
Application Number : 2512912
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : PHESGO
Dosage Form : SOLUTION
Dosage Strength : 60MG/ML
Packaging :
Approval Date :
Application Number : 2512920
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : TRAZIMERA
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 440MG/VIAL
Packaging :
Approval Date :
Application Number : 2483467
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ONTRUZANT
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 150MG/VIAL
Packaging :
Approval Date :
Application Number : 2524317
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : ONTRUZANT
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 440MG/VIAL
Packaging :
Approval Date :
Application Number : 2524325
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : OGIVRI
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 150MG/VIAL
Packaging :
Approval Date :
Application Number : 2474425
Regulatory Info : Prescription
Registration Country : Canada
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Herzuma
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Herzuma
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Herzuma
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Herzuma
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Herzuma
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Kanjinti
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Trazimera
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Trazimera
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Trazimera
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Ogivri
Dosage Form :
Dosage Strength :
Packaging : 1
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]South Africa
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Trastuzumab Cipla 440 mg
Dosage Form : INJ
Dosage Strength : 440mg
Packaging : 21X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Phesgo FDC 1200
Dosage Form : SOL
Dosage Strength : 600mg
Packaging : 15X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Phesgo FDC 600
Dosage Form : SOL
Dosage Strength : 600mg
Packaging : 10X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Herceptin SC 600mg
Dosage Form : INJ
Dosage Strength : 600mg/5ml
Packaging : 5X1mg/5ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Herceptin 21 mg/ml IV
Dosage Form : INJ
Dosage Strength : 440mg
Packaging : 21X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : OGIVRI 440
Dosage Form : INJ
Dosage Strength : 440mg
Packaging : 21X1mg
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Regulatory Info :
Registration Country : Iran
Brand Name : AryoTrust
Dosage Form : Injectable
Dosage Strength : 150MG
Packaging : Vial
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging : Vial
Regulatory Info :
Dosage : Injectable
Dosage Strength : 150MG
Brand Name : AryoTrust
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : AryoTrust
Dosage Form : Injectable
Dosage Strength : 440MG
Packaging : Vial
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging : Vial
Regulatory Info :
Dosage : Injectable
Dosage Strength : 440MG
Brand Name : AryoTrust
Approval Date :
Application Number :
Registration Country : Iran
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Nanjing Well Pharmaceutical
Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.
Dosage Form : Cream / Lotion / Ointment
Grade : Parenteral, Oral, Topical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Solubilizers
Parenteral
Topical
Surfactant & Foaming Agents
Taste Masking
Emulsifying Agents
Thickeners and Stabilizers
Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
